CAMP4 receives Australian TGA clearance for CMP-002 Phase 1/2 trial; triggers $50M second closing

Camp4 Therapeutics Corp

• TGA and HREC clearance to initiate first-in-human Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder.
• Milestone triggers second closing of September 2025 private placement; up to $50M gross proceeds.
• Second closing expected on or about August 3, 2026; up to 32.7M shares (or pre-funded warrants) to be issued.
• Investors committed include Coastlands Capital, Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures, Adage, Trails Edge, CURE SYNGAP1.
• Australia selected as first site; company pursuing additional international regulatory filings.